AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
https://www.eurekalert.org/news-releases/1115824
Publish Date: 2026-02-10 08:17:00
Source Domain: www.eurekalert.org
-
Collaboration Announcement:
- Insilico Medicine and China Medical System Holdings (CMS) announced a collaboration to advance AI-powered drug development.
-
AI Integration:
- The collaboration leverages Insilico’s AI platform and AI-driven drug discovery capabilities alongside CMS’ extensive R&D expertise and disease-area knowledge.
-
Joint R&D Programs:
- The partnership aims to co-develop at least two R&D programs focused on central nervous system and autoimmune diseases.
-
Funding Support:
- Insilico is set to receive up to several tens of millions of Hong Kong dollars in R&D funding for each program.
-
Objective:
- The collaboration seeks to accelerate drug discovery, clinical development, and commercialization while improving patient access to innovative therapies.
-
Shortening Development Timelines:
- By combining resources and expertise, the collaboration aims to shorten development timelines and enhance clinical success rates.
-
Vision for Future Collaboration:
- Both companies intend to deepen their collaboration across pipeline development, clinical strategies, and global partnerships to further improve accessibility to innovative medicines.
